Novavax (NVAX)

Company Description

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates.


 

COMPANY ADDRESS
9920 Belward Campus Drive
Rockville, Maryland 20850
United States

COMPANY PHONE
240-268-2000

COMPANY WEBSITE



Get BioInvest's perspective on Novavax's CEO


Latest Company News

Worthy Stock in the Spotlight: Novavax Inc (NVAX) Post Registrar - 5 hours ago Novavax Inc (NASDAQ:NVAX) shares traded on 0.85% up secure line and closed at $1.19. The stock exchanged hands 2.91 Million shares versus average trading capacity of 6.36 Million shares. Novavax, Inc. (NVAX) closed the last trading session with surged of 0.85 percent - StandardOracle [...]
Tue, Jun 27, 2017 4:41:00 PM, Continue reading at the source
Novavax, Inc. (NVAX) Has Revealed It All In Its Chart NY Stock News - 9 hours ago The technicals for Novavax, Inc. (NVAX) have taken shape, and with them a comprehensive picture has emerged. This is the current state of play as presented by the current technical setup. [...]
Tue, Jun 27, 2017 1:18:00 PM, Continue reading at the source
Why Investors remained confident on Sunstone Hotel Investors, Inc. (SHO ... StockNewsJournal - 9 hours ago Novavax, Inc. (NASDAQ:NVAX), maintained return on investment for the last twelve months at -59.67, higher than what Reuters data shows regarding industry's average. Is It Undervalued? Look at the P/E Ratio: Sunstone Hotel Investors, Inc. (SHO ... - AllStockNews Stifel Financial Corp Has $627000 Position in Sunstone Hotel Investors, Inc. (SHO) - AppsforPCdaily [...]
Tue, Jun 27, 2017 12:45:00 PM, Continue reading at the source
Novavax Inc Risk Points versus Health Care CML News - Jun 23, 2017 This is a scatter plot analysis of the critical risk points from the option market for Novavax Inc (NASDAQ:NVAX) compared to its own past and the Health Care ETF. [...]
Fri, Jun 23, 2017 9:45:00 PM, Continue reading at the source
Sentiment Turns Bullish on Novavax, Inc. (NASDAQ:NVAX) The Oracle Dispatch - Jun 23, 2017 Novavax, Inc. (NASDAQ:NVAX) has finally stung together a few positive months. What started with a horrific week back in September 2016 (where Novavax's shareprice dropped from a high of $8.49 to a low of $1.16), turned even uglier and the downward ... Novavax, Inc. (NVAX) Showcases What It Has To Offer Via The Technical Chart - NY Stock News [...]
Fri, Jun 23, 2017 4:07:00 PM, Continue reading at the source
Novavax, Inc. (NVAX) sees -19.86% decrease in 50-day volume NY Stock News - Jun 23, 2017 Novavax, Inc. (NVAX) is looking very interesting as a trading opportunity right now. The technical setup offers the best window into what traders can expect whether they are bullish on the play or bearish. [...]
Fri, Jun 23, 2017 11:48:00 AM, Continue reading at the source
Is It Time to go for Novavax, Inc. (NVAX), Alliqua BioMedical, Inc. (ALQA)? StockNewsJournal - Jun 20, 2017 Investors who are keeping close eye on the stock of Novavax, Inc. (NASDAQ:NVAX) established that the company was able to keep return on investment at -59.67 in the trailing twelve month while Reuters data showed that industry's average stands at -8.46 ... [...]
Tue, Jun 20, 2017 11:15:00 AM, Continue reading at the source
These 2 Catalysts Are Behind Novavax, Inc.'s 12% Rise in May Motley Fool - Jun 7, 2017 Shares of Novavax (NASDAQ:NVAX), a clinical-stage biotech focused on the development of recombinant nanoparticle vaccines and adjuvants for the treatment of respiratory syncytial virus, surged 12% during the month of May, according to data from S&P ... Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing ... - PR Newswire (press release) Novavax Inc. (NVAX) Moves Higher on Volume Spike for June 07 - Equities.com [...]
Wed, Jun 07, 2017 3:11:00 PM, Continue reading at the source
Novavax Continues To Demonstrate Bright Growth Prospects In 2017 Seeking Alpha - Jun 5, 2017 However, compared to the peak sales value of $1.5 billion projected for the maternal RSV F vaccine by Novavax in its Q1 2017 earnings conference call, my projections seem too conservative. Novavax, Inc. (NVAX) CFO Buys $21000.00 in Stock - The Cerbat Gem Novavax, Inc. (NVAX) hit its 1-Year High price on 09/15/16 - TopChronicle [...]
Mon, Jun 05, 2017 7:07:00 PM, Continue reading at the source
Novavax's Pipeline: Plenty Of Ammunition Seeking Alpha - Jun 1, 2017 Widespread misinformation in articles and comments has caused fear among investors, resulting in a great buying opportunity. One of the main areas of incorrect information is the claim that Novavax had only one backup or no backups to its older adults ... Financial Review Of Novavax, Inc. (NASDAQ:NVAX) - FinancialsTrend Novavax Inc. (NVAX) Soars 12.88% on June 01 - Equities.com [...]
Thu, Jun 01, 2017 5:03:00 PM, Continue reading at the source